Trevi Therapeutics (TRVI) Tops Q3 EPS by 6c

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.34), $0.06 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• AB Science reports phase 1 data for AB8939 plus venetoclax in AML
• EU panel backs Hopledo for Parkinson's motor fluctuations